Teaching an old dog new tricks: Potential antiatherothrombotic use for statins

Journal of Clinical Investigation

Volumn 122, Issue 2, 2012, Pages 478-481

  Silverstein, Roy L ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD36 ANTIGEN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OXIDIZED LOW DENSITY LIPOPROTEIN; ROSUVASTATIN;

ANTICOAGULATION; ATHEROSCLEROSIS; ATHEROTHROMBOSIS; CHOLESTEROL BLOOD LEVEL; GENETIC POLYMORPHISM; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; MONOCYTE; NONHUMAN; NOTE; OXIDATIVE STRESS; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; THROMBOCYTE; THROMBOSIS;

ANIMALS; ANTICHOLESTEREMIC AGENTS; BLOOD COAGULATION; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MONOCYTES; SIMVASTATIN; THROMBOPLASTIN;

EID: 84856545957     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI61857     Document Type: Note

References (24)

1. Owens AP III, et al. Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin. J Clin Invest. 2012;122(2):558-568.
2. Rocha VZ, Libby P. Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol. 2009;6(6):399-409.
3. Chisolm GM, Steinberg D. The oxidative modification hypothesis of atherogenesis: an overview. Free Radic Biol Med. 2000;28(12):1815-26. (Pubitemid 30628668)
4. Silverstein RL, Febbraio M. CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Sci Signal. 2009;2(72):re3.
5. Park YM, Febbraio M, Silverstein RL. CD36 modulates migration of mouse and human macrophages in response to oxidized LDL and contributes to macrophage trapping in the arterial intima. J Clin Invest. 2009;119(1):136-145.
6. Li W, Febbraio M, Reddy SP, Yu D-Y, Yamamoto M, Silverstein RL. CD36 participates in a signaling pathway that regulates reactive oxygen species formation by vascular smooth muscle cells. J Clin Invest. 2010;120(11):3996- 4006.
7. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 1998;93(2):241-252. (Pubitemid 28180857)
8. Febbraio M, et al. Targeted disruption of the Class B scavenger receptor, CD36, protects against atherosclerotic lesion development in mice. J Clin Invest. 2000;105(8):1049-1056. (Pubitemid 30217689)
9. Manning-Tobin JJ, et al. Loss of SR-A and CD36 activity reduces atherosclerotic lesion complexity without abrogating foam cell formation in hyperlipidemic mice. Arterioscler Thromb Vasc Biol. 2009;29(1):19-26.
10. Shaw PX, et al. Human-derived anti-oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo. Arterioscler Thromb Vasc Biol. 2001;21(8):1333-1339. (Pubitemid 34219841)
11. Ridker PM, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-2207.
12. Mihos CG, Salas MJ, Santana O. The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in cardiovascular disease: a comprehensive review. Cardiol Rev. 2010;18(6):298-304.
13. Mandosi E, et al. Atorvastatin downregulates monocyte CD36 expression, nuclear NFkappaB and TNFalpha levels in type 2 diabetes. J Atheroscler Thromb. 2010;17(6):539-545.
14. Tuomisto TT, et al. Simvastatin has an anti-inflammatory effect on macrophages via upregulation of an atheroprotective transcription factor, Kruppel-like factor 2. Cardiovasc Res. 2008;78(1):175-184. (Pubitemid 351430960)
15. Podrez EA, et al. Platelet CD36 links hyperlipidemia, oxidant stress and a pro-thrombotic phenotype. Nat Med. 2007;13(9):1086-1095. (Pubitemid 47517507)
16. Korporaal SJ, et al. Platelet activation by oxidized low density lipoprotein is mediated by CD36 and scavenger receptor-A. Arterioscler Thromb Vasc Biol. 2007;27(11):2476-2483. (Pubitemid 350203967)
17. Ghosh A, Li W, Febbraio M, Espinola RG, McCrae K, Silverstein RL. Platelet CD36 mediates interactions with endothelial cell-derived microparticles and contributes to thrombosis in vivo. J Clin Invest. 2008;118(5):1934-1943. (Pubitemid 351632395)
18. Knowles JW, et al. Association of polymorphisms in platelet and hemostasis system genes with acute myocardial infarction. Am Heart J. 2007;154(6):1052-1058. (Pubitemid 350116028)
19. Love-Gregory L, et al. Common CD36 SNPs reduce protein expression and may contribute to a protective atherogenic profile. Hum Mol Genet. 2011;20(1):193-201.
20. Ghosh A, et al. Platelet CD36 surface expression levels affect functional responses to oxidized LDL and are associated with inheritance of specific genetic polymorphisms. Blood. 2011;117(23):6355-6366.
21. Rahaman SO, Lennon DJ, Febbraio M, Podrez EA, Hazen SL, Silverstein RL. CD36-dependent activation of c-Jun N-terminal kinase by oxidized LDL is required for macrophage foam cell formation. Cell Metab. 2006;4(3):211-221.
22. Chen K, Li W, Major J, Febbraio M, Silverstein RL. Vav guanine nucleotide exchange factors link hyperlipidemia and a prothrombotic state. Blood. 2011;117(21):5744-5750.
23. Seimon TA, et al. Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab. 2010;12(5):467-482.
24. Stewart CR, et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol. 2010;11(2):155-161.